Motixafortide
Motixafortide is a pharmaceutical drug with 7 clinical trials. Currently 4 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
2
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
2 of 2 finished
0.0%
0 ended early
4
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Gene Editing For Sickle Cell Disease
SCD Stem Cell Mobilization and Apheresis Using Motixafortide
Motixafortide for MRD Sensitization in AML
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization
Clinical Trials (7)
Gene Editing For Sickle Cell Disease
SCD Stem Cell Mobilization and Apheresis Using Motixafortide
Motixafortide for MRD Sensitization in AML
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization
Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7